Grant: DRA: Canada Impact+ Research Training Awards - Doctoral
Université de Montréal
$120,000.00
Targeting the KSR2 Scaffold to Control Cancer Cell Motility and Metastasis
EF 2025-26
Résumé
"The MAPK pathway is one of the most well-defined drivers of cancer and is hyperactivated in over 40% of human cancer cases. Targeted therapies against this pathway have improved patient outcomes, however the emergence of drug resistance often limits their long-term effectiveness. Central to this signaling cascade are the RAF/KSR family kinases, key regulators of signal transmission that represent promising avenues for developing more durable cancer treatments.
This research project focuses on the KSR2 (Kinase Suppressor of Ras 2) pseudo-kinase, extensively studied in the laboratory of Dr Marc Therrien (main supervisor of the proposed project). Rather than acting as an active enzyme, KSR2 functions as a molecular scaffold, binding MEK and ERK to activate the MAPK pathway. Because of this scaffold function, targeting KSR2 may offer a new way to disrupt cancer signaling while limiting drug resistance.
Using the AI-accelerated molecular docking pipeline from the laboratory of Dr Olivier Mailhot (co-supervisor of the proposed project), I will perform a virtual screen of ~100 billion synthesis-on-demand small molecules against the experimental ligand-bound structure of KSR2 (PDB ID 5KKR). A set of ~50 diverse, top-scoring docking hits will be ordered for synthesis and tested in laboratory experiments. First, I will use a biochemical ATP displacement assay to determine whether the compounds bind KSR2. I will further study confirmed hits in cancer cell lines to assess whether they reduce cell growth and motility. Medicinal chemistry optimization will be performed on the best compounds to optimize their potency. Finally, the top candidates will be studied in mouse models through IRIC’s In vivo biology platform to assess their ability to reduce tumor growth and invasion."
Programme
DRA: Canada Impact+ Research Training Awards - Doctoral
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
568227
Name
Aziz Shahkaar
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Canada Impact+ Research Training Awards - Doctoral
Projecttitle
Targeting the KSR2 Scaffold to Control Cancer Cell Motility and Metastasis
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA: Canada Impact+ Research Training Awards - Doctoral
Keyworddelim
Drug Resistance; Ksr2; Mapk Signalling; Metastasic Cancer; Molecular Docking; Pseudo-Kinases; Virtual Screening
Abstract
"The MAPK pathway is one of the most well-defined drivers of cancer and is hyperactivated in over 40% of human cancer cases. Targeted therapies against this pathway have improved patient outcomes, however the emergence of drug resistance often limits their long-term effectiveness. Central to this signaling cascade are the RAF/KSR family kinases, key regulators of signal transmission that represent promising avenues for developing more durable cancer treatments.
This research project focuses on the KSR2 (Kinase Suppressor of Ras 2) pseudo-kinase, extensively studied in the laboratory of Dr Marc Therrien (main supervisor of the proposed project). Rather than acting as an active enzyme, KSR2 functions as a molecular scaffold, binding MEK and ERK to activate the MAPK pathway. Because of this scaffold function, targeting KSR2 may offer a new way to disrupt cancer signaling while limiting drug resistance.
Using the AI-accelerated molecular docking pipeline from the laboratory of Dr Olivier Mailhot (co-supervisor of the proposed project), I will perform a virtual screen of ~100 billion synthesis-on-demand small molecules against the experimental ligand-bound structure of KSR2 (PDB ID 5KKR). A set of ~50 diverse, top-scoring docking hits will be ordered for synthesis and tested in laboratory experiments. First, I will use a biochemical ATP displacement assay to determine whether the compounds bind KSR2. I will further study confirmed hits in cancer cell lines to assess whether they reduce cell growth and motility. Medicinal chemistry optimization will be performed on the best compounds to optimize their potency. Finally, the top candidates will be studied in mouse models through IRIC’s In vivo biology platform to assess their ability to reduce tumor growth and invasion."
Competitiondate
202603
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Aziz, Shahkaar
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~